Results. Among patients with MSSA bacteremia and a self-reported penicillin allergy, skin testing produced the best clinical outcomes and was cost-effective relative to history screening, generating 0.51 additional QALYs at an ICER of $22,062 per QALY gained. Among patients with diabetes, malignancy, or ESRD, the ICER for skin testing relative to history screening increased to $30,830–$127,182, reflecting the overall lower lifetime expectancy and high annual survivor healthcare cost in these higher risk groups. Results were robust to wide variations in the cost and diagnostic performance of skin testing; in sensitivity analyses, skin testing remained the optimal strategy when cost was <$5,000, specificity >60%, and sensitivity >10%.

Conclusion. Among adults with MSSA bacteremia and a self-reported β-lactam allergy, skin testing is cost-effective relative to history screening and routine care at conventional willingness-to-pay thresholds and should be widely adopted given the mortality benefit of β-lactams over alternate antibiotics in MSSA bacteremia.

Figure 1: Costs and Effectiveness of Three Strategies by Baseline and Coinfection States

Disclosures. All authors: No reported disclosures.

1789. Inpatient Penicillin Skin Testing: Outcomes From a Propensity-Matched Case–Control Study

Christina Sarubbi, PharmD; Rebekah Wrenn, PharmD; Nicholas Turner, MD; Renee Lugar, MD; Jessica Seidelman, MD; Patricia Lugar, MD; Cristina Radojicic, MD; Rebekah W. Moehring, MD, MPH1; and Deverick J. Anderson, MD, MPH, FIDSA, FSHEA1; 1Duke Center for Antimicrobial Stewardship and Infection Prevention, Durham, North Carolina, 2Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, 3Department of Pediatrics, Division of Allergy and Immunology, Durham, North Carolina, 4Department of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, Durham, North Carolina, 5Allergy and Immunology, Duke University Health System, Durham, North Carolina

Session: 217. Antimicrobial Stewardship: Impact of Allergy Thursday, October 4, 2018: 12:30 PM

Background. Nearly 10% of patients report an allergy to penicillin, yet fewer than 10% are confirmed to have a true allergy. Reported allergy frequently leads to the use of costly, broad-spectrum or less-effective antibiotics. We launched a penicillin skin testing (PST) service offering real-time skin testing for inpatients. Here we present clinical outcomes for the two years following enrollment.

Methods. PST was performed on 80 adults with a reported penicillin allergy admitted to Duke University Hospital between November 2016 and March 2018. A logistic regression model predicting PST receipt was developed using a cohort of penicillin-allergic, untested adults. Covariates included age, gender, diagnosis, and Charlson co-morbidity index. Using this model, the PST cases were propensity-matched 1:1 with untested, penicillin-allergic controls admitted in the preceding year (October 2015–October 2016). Rates of first-line antibiotic receipt were compared between PST cases and their propensity-matched controls.

Results. PST cases and controls had similar demographics, reported allergies, diagnoses, and co-morbidities. Cases were more likely to receive a first-line antibiotic (83% vs. 57%, P = 0.003, Table 1). Rates of clinical cure were similar between groups. Ninety-day recurrence and C. difficile infection were numerically higher in the untested group but did not reach statistical significance. A single allergic reaction (rash upon receipt of a cephalosporin) occurred in the PST group.

Conclusion. Penicillin skin-testing significantly increased the proportion of patients receiving first-line antibiotics. While rates of recurrence and C. difficile infection were lower for skin-tested patients, these differences did not reach statistical significance. As this study was not expressly powered to detect such differences, we plan to re-assess these outcomes once we have accrued a sufficiently large cohort of tested patients.

Table 1: Outcomes.

| Clinical outcomes | PST (N = 80) | Matched (N = 80) | P-value |
|-------------------|-------------|-----------------|--------|
| First-line antibiotics | 53 (66.3)   | 31 (39.0)       | 0.003  |
| Clinical cure      | 58 (72.5)   | 57 (71.3)       | 0.48   |
| 90-day recurrence  | 3 (3.8)     | 8 (10.0)        | 0.13   |
| C. difficile infection | 2 (2.5)    | 4 (5.0)         | 0.40   |
| Allergic reaction  | 1 (1.2)     | 0 (0.0)         | 0.32   |

Disclosures. All authors: No reported disclosures.

1790. Clinical and Economic Outcome Evaluation with Penicillin Skin Testing as an Antimicrobial Stewardship Initiative in a Not-for-Profit Community Health System

Bruce M Jones, PharmD, BCPS1; Abigail Hamlin, PharmD Candidate2; Joseph Crosby, PhD, RPh1 and Christopher Bland, PharmD, BCPS, FIDSA2; 1St. Joseph’s/Candler Health System, Savannah, Georgia, 2Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Savannah, Georgia

Session: 217. Antimicrobial Stewardship: Impact of Allergy Saturday, October 6, 2018: 12:30 PM

Background. Penicillin skin testing (PST) is a novel way to reduce the use of broad-spectrum agents, potentially resulting in unnecessary overuse and cost savings. This study evaluated clinical and economic outcomes of antimicrobials prescribed with and without PST in a community health system.

Methods. This quasi-experimental study compared an experimental group of 100 adult patients who completed PST for a self-reported penicillin allergy over an open enrollment period beginning January 2016 to a matched control group of 100 patients over the same time frame that had a listed penicillin allergy as well as consultation with infectious diseases. Patients in the control group were matched to the infection diagnosis codes of the members of experimental group and then randomly selected and matched on a 1:1 basis. The primary outcome was β-lactam days of therapy (DOT) defined as either a penicillin or cephalosporin (not carbapenem). The secondary outcome assessed the average cost of antimicrobial therapy before and after PST.

Results. The control group consisted of 436 patients who met inclusion criteria with 100 patients from that group matched to the 100 patients in the PST group by diagnosis code. The most common self-reported allergy consisted of IgE-mediated (52%) and unknown (30%) in the PST group and IgE-mediated (33%), unknown (20%), and rash (32%) in the control group. Ninety-eight of 100 patients who underwent PST tested negative, with 71 out of 98 (73%) having changes directly made to their antimicrobial regimen immediately after PST. β-lactam DOT for the control group consisted of 386 out of 984 (39.64%, with 6.4% being a penicillin specifically). Chi-square test of homogeneity for β-lactam DOT between the two groups was significant (P < 0.00001). Changes to the antimicrobial regimen after PST saved the average patient $353.03 compared with no change in pre-PST regimen (P = 0.045).

Conclusion. PST led to immediate antimicrobial de-escalation in the majority of patients who tested negative. This led to a significant increase in β-lactam usage, specifically penicillins. These benefits were also associated with significant cost savings to patients, justifying the cost of performing PST.

Disclosures. B. M. Jones, ALK: Consultant, Grant Investigator and Speaker’s Bureau, Consulting fee, Grant recipient and Speaker honorarium. C. Bland, ALK: Grant Investigator and Speaker’s Bureau, Grant recipient and Speaker honorarium.

1791. The Impact of a β-lactam Allergy Assessment on Aztreonam Utilization Within a Healthcare System

Katherine Shea, PharmD, BCPS AQ-ID1; Tamara Knight, PharmD2; Therese Jaso, PharmD3; and Athena L. V. Hobs, PharmD4; 1Cardinal Health, Innovative Delivery Solutions, Houston, Texas, 2Seton Healthcare Family, Austin, Texas, 3Austin Infectious Disease Consultants, Austin, Texas, 4Department of Pharmacy, Baptist Memorial Hospital—Memphis, Memphis, Tennessee

Session: 217. Antimicrobial Stewardship: Impact of Allergy Saturday, October 6, 2018: 12:30 PM

Background. An Antimicrobial Stewardship Initiative in a Not-for-Profit Community Health System

Joseph’s/Candler Health System, Savannah, Georgia

Session: 217. Antimicrobial Stewardship: Impact of Allergy Saturday, October 6, 2018: 12:30 PM

Background. Penicillin skin testing (PST) is a novel way to reduce the use of broad-spectrum agents, potentially resulting in unnecessary overuse and cost savings. This study evaluated clinical and economic outcomes of antimicrobials prescribed with and without PST in a community health system.

Methods. This quasi-experimental study compared an experimental group of 100 adult patients who completed PST for a self-reported penicillin allergy over an open enrollment period beginning January 2016 to a matched control group of 100 patients over the same time frame that had a listed penicillin allergy as well as consultation with infectious diseases. Patients in the control group were matched to the infection diagnosis codes of the members of experimental group and then randomly selected and matched on a 1:1 basis. The primary outcome was β-lactam days of therapy (DOT) defined as either a penicillin or cephalosporin (not carbapenem). The secondary outcome assessed the average cost of antimicrobial therapy before and after PST.

Results. The control group consisted of 436 patients who met inclusion criteria with 100 patients from that group matched to the 100 patients in the PST group by diagnosis code. The most common self-reported allergy consisted of IgE-mediated (52%) and unknown (30%) in the PST group and IgE-mediated (33%), unknown (20%), and rash (32%) in the control group. Ninety-eight of 100 patients who underwent PST tested negative, with 71 out of 98 (73%) having changes directly made to their antimicrobial regimen immediately after PST. β-lactam DOT for the control group consisted of 386 out of 984 (39.64%, with 6.4% being a penicillin specifically). Chi-square test of homogeneity for β-lactam DOT between the two groups was significant (P < 0.00001). Changes to the antimicrobial regimen after PST saved the average patient $353.03 compared with no change in pre-PST regimen (P = 0.045).

Conclusion. PST led to immediate antimicrobial de-escalation in the majority of patients who tested negative. This led to a significant increase in β-lactam usage, specifically penicillins. These benefits were also associated with significant cost savings to patients, justifying the cost of performing PST.

Disclosures. B. M. Jones, ALK: Consultant, Grant Investigator and Speaker’s Bureau, Consulting fee, Grant recipient and Speaker honorarium. C. Bland, ALK: Grant Investigator and Speaker’s Bureau, Grant recipient and Speaker honorarium.

1791. The Impact of a β-lactam Allergy Assessment on Aztreonam Utilization Within a Healthcare System

Katherine Shea, PharmD, BCPS AQ-ID1; Tamara Knight, PharmD2; Therese Jaso, PharmD3; and Athena L. V. Hobs, PharmD4; 1Cardinal Health, Innovative Delivery Solutions, Houston, Texas, 2Seton Healthcare Family, Austin, Texas, 3Austin Infectious Disease Consultants, Austin, Texas, 4Department of Pharmacy, Baptist Memorial Hospital—Memphis, Memphis, Tennessee
Background. Penicillin allergies are the most commonly reported drug allergies and are documented in up to 17% of patients. Incomplete reaction histories and exaggerated concerns regarding the risk of cross-reactivity often lead to unnecessary avoidance of β-lactams in patients with reported allergies. Utilization of alternative non-β-lactam therapy in patients with reported allergies has been associated with increased incidence of multidrug-resistant organisms, including *C. difficile* infection. Per the Infectious Diseases Society of America guidelines for implementing an antibiotic stewardship program (ASP), ASPs should promote allergy assessments and penicillin skin testing in patients with a history of a β-lactam allergy. Implementation of penicillin skin testing in the acute care setting is often limited by lack of education, skill, and time required in administering and interpreting the result. Investigators sought to assess the impact of a β-lactam allergy assessment on aztreonam utilization within a healthcare system.

Methods. This is a multicenter, retrospective study comparing aztreonam utilization in five hospitals within a healthcare system after implementation of a β-lactam allergy assessment. The program included education as well as development of criteria for utilization and a β-lactam allergy assessment algorithm. A β-lactam allergy assessment was performed on any patient with an order for aztreonam. The Mann–Whitney U test was used to assess the impact of the restriction program on aztreonam utilization and expenditure.

Results. The hospital system experienced roughly a 50% decrease in aztreonam days of therapy per 1,000 patient-days [P < 0.01] and 67% reduction in annual expenditure [P < 0.05]. Of the 204 patients with an order for aztreonam, 151 (74%) patients received at least one dose; however, 97 (48%) patients ultimately received and tolerated a β-lactam. Only 112 (55%) patients had a prior reported reaction with 68 (61%) of those having a history of a Type I reaction.

Conclusion. Implementation of a β-lactam allergy assessment for patients with reported allergies can enhance appropriate use of β-lactams and result in reduced aztreonam utilization and expenditure.

Disclosures. All authors: No reported disclosures.

1792. Assessing Outcomes of Antimicrobial Stewardship Interventions Along With a Hospital-Wide β-Lactam Allergy Guideline Through Aztreonam Use: A 5-Year Observation

Shane B., Wang, PharmD, BCPS; Sarah Won, MD, MPH; Sindharda Bandi, MD; Mary Tobin, MD; Michael Beshir, PharmD; Shyama Ravindran, PharmD; Beth Shields, PharmD; Tristan O’Driscoll, PharmD; Hung Li Lu, PharmD Candidate; Amy Hanson, PharmD, BCPS AQ-ID; Christy Varughese, PharmD, BCPS; John Segreti, MD, FIDSA, FSHM; Prashant Pawar, MD, Midwestern University, Chicago College of Pharmacy, Downers Grove, Illinois, 1Department of Pharmacy, Rush University Medical Center, Chicago, Illinois, 2Department of Internal Medicine, Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois, 3Department of Internal Medicine, Division of Allergy and Immunology, RUSH University Medical Center, Chicago, Illinois, 4Department of Internal Medicine, Division of Allergy and Immunology, RUSH University Medical Center, Chicago, Illinois, 5Department of Pharmacy, RUSH University Medical Center, Chicago, Illinois, 6Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Downers Grove, Illinois, 7Division of Infectious Diseases, Rush University Medical Center, Chicago, Illinois

Session: 217. Antimicrobial Stewardship: Impact of Allergy Saturday, October 6, 2018: 12:30 PM

Background. Aztreonam (AZT) is an alternative antibiotic for Gram-negative infections requiring IV therapy and anti-pseudomonal coverage in patients with an IgE mediated penicillin allergy. However, many reported allergic reactions to penicillins are either unknown or mis-categorized. In 2012, significant use of AZT was observed at our institution coupled with a 29% resistance rate for *Pseudomonas aeruginosa* (PA) to AZT. The aim of this study was to track and assess AZT use during a 5-year period during which antimicrobial stewardship interventions along with a hospital-wide β-lactam allergy guideline were implemented to optimize β-lactam use.

Methods. A retrospective review of AZT use was conducted at Rush University Medical Center from January 2012 to December 2017. September of 2012, AZT was restricted for use in patients with an immediate-type 1 hypersensitivity reaction to a β-lactam (BL) with approval from the infectious diseases (ID) consult service. January 2015, a β-lactam allergy assessment and de-labeling of PCN allergies, they are not feasible at all institutions. An alternative solution is to conduct a detailed penicillin allergy interview (PAST), which can potentially lead to de-escalation and/or optimization of antimicrobial therapy.

Methods. Pharmacist-driven PASTs were conducted between December 26, 2017 and March 26, 2018. Adult patients admitted with a documented PCN allergy were interviewed according to a standardized questionnaire. The allergy profile within the PAST was updated and a recommendation to switch to non-carbapenem β-lactam therapy was made to the prescriber based on a decision algorithm. Objectives of this study include characterization of changes made to the allergy profile within the EHR after PAST and measuring the number of patients successfully switched to β-lactam therapy.

Results. A total of 466 patients were admitted with a documented PCN allergy, of which 175 (37.5%) received PAST. Of these patients, 133 (76%) required a change to their allergy profile (Table 1). One-hundred thirty-five (77.1%) patients interviewed were an antimicrobial agent (Figure 1). Forty-two patients (31.1%) met criteria to switch to non-carbapenem β-lactam therapy, and 31 (73.8%) patients were successfully switched with no adverse events noted.

Conclusion. A large number of admitted patients with a documented PCN allergy received a DPAI. Implementation of pharmacist-driven PASTs led to updated, more accurate allergy information within the EHR, as well as de-escalation and/or optimization of antimicrobial therapy. Provider acceptance rate to switch to non-carbapenem β-lactam therapy was high.